China's Connect Eyes Partnerships To Globalize Dermatitis Biologic
CEO Wants To Unlock Main Value Outside Home Market
Executive Summary
Watch out Sanofi. US- and China-based Connect BioPharma is looking to position its novel biologic for atopic dermatitis to compete head-on with best-selling Dupixent both inside and outside China in an increasingly crowded space, says co-founder and CEO Wei Zheng in an exclusive interview with Scrip.